drugset / Trial / NCT02226926

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

NCT02226926

Phase 1 Completed 15 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Investigation of the mechanism of dipyridamole action in platelets in an in-vivo study with healthy volunteers treated Aggrenox in comparison with volunteers treated with Persantin Retard or Acetylsalicylic Acid using platelet Vasodilator-Stimulated-Phosphoprotein (VASP)-phosphorylation as indication for an action and measurements of dipyridamole plasma levels

Timeline

Start
2000-07
Primary completion
2000-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule
Subject Dipyridamole Other / unclassified

Indications

No indication recorded.